Episode

Episode 158 - Daniel Hader - Model Medicines

Podcast
The BioHub - by Avetix
Published
Apr 22, 2026
Duration seconds
2711
Processing state
not_requested
Canonical source
https://podcasters.spotify.com/pod/show/max-brennan4/episodes/Episode-158---Daniel-Hader---Model-Medicines-e3i8lm8
Audio
https://anchor.fm/s/f0076084/podcast/play/118822024/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-3-22%2F422591580-44100-2-42cc3965d02cc.mp3
JSON
/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-158-daniel-hader-model-medicines
Markdown
/podcast/the-biohub-by-avetix-7252289/episode-158-daniel-hader-model-medicines.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-158-daniel-hader-model-medicines/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/the-biohub-by-avetix-7252289/episode-158-daniel-hader-model-medicines.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

In this episode of the BioHub Podcast, Amber is joined by Daniel, Co-Founder and CEO of Model Medicines. Model Medicines is building an AI-driven drug discovery platform with a fundamentally different approach, focusing on applying machine learning to problems where traditional methods have failed. Daniel shares how the team is targeting biological “choke points” across multiple diseases, why throughput and inference may matter more than model size, and how they’re thinking about scaling into development as programmes move towards the clinic.